Satricabtagene autoleucel (Satri-cel, CT041) chigadzirwa cheCAR T-cell chinorwisa puroteni inonzi Claudin18.2 iyo inogona kuva yepamusoro-soro pasi rose. Satri-cel inodzivirira Claudin18.2 solid bundu, ichinyanya kutarisa kenza yemudumbu/gastroesophageal junction cancer (GC/GEJ) uye kenza yepancreatic (PC).
Mhedzisiro yekupedzisira yekuedzwa kwakatangwa nemuongorori CT041-CG4006 (NCT03874897) ye satricabtagene autoleucel yakabudiswa muNature Medicine musi wa3 Chikumi, 2024.
Varwere vanosvika 98 vakapinda muongororo iyi, uye mhedzisiro yakaratidza kuti chiyero chekudzivirira chirwere (DCR) chakakwira kusvika 91.8%, varwere makumi matatu nevasere vakawana relief, chiyero cherelief chese chaive 38.8%, medium progression free survival (PFS) yaive mwedzi 4.4, medium overall survival (OS) yaive mwedzi 8.8, uye medium duration of relief (mDOR) yaive mwedzi 6.4. Pakati pevarwere makumi mapfumbamwe vane lesion yekutanga, varwere makumi manomwe vakawana diki rebundu rakasiyana-siyana.
Pakati pevarwere vegomarara remudumbu makumi mashanu nerimwe vakarapwa neSatri-cel imwe chete, mwero wekudzivirira chirwere wakakwira kusvika pa96.1% (49), uye mwero wemhinduro yese waive 54.9% (28). Pakati pavo, varwere makumi maviri nevanomwe vakawana mhinduro isina chikamu (PR), murwere mumwe chete akawana mhinduro yakazara (CR), uye nguva yepakati yemhinduro (mDOR) yaive mwedzi 6.4.
Mhedziso
Satri-cel inoratidza kugona kwekurapa nekuchengetedza kwakasimba muvarwere vane kenza yemudumbu ine CLDN18.2-positive.
Musi wa9 Gunyana, 2023, nyaya mbiri dzekurapa kenza yepancreatic yakapararira neCARsgen's CT041, iyo Claudin (CLDN) 18.2 CAR T-cell Therapy itsva, dzakaburitswa muJournal of Hematology & Oncology ine musoro unoti “CT041 CAR T cell therapy for Claudin18.2 positive metastatic pancreatic cancer”.
Muchiitiko chekutanga, mukadzi ane makore makumi mashanu nemasere ekuberekwa akaonekwa aine kenza yepancreatic ine metastasis yemapapu nelymph nodes. Nab-paclitaxel yekutanga pamwe negemcitabine uye irinotecan-liposome yechipiri pamwe ne5-flurouracil zvakakundikana asati anyoreswa muongororo yekiriniki yeCT041, mushure mekusimbisa CLDN18.2 se2+/70%. Mushure me lymphodepletion ine fludarabine, cyclophosphamide, uye nab-paclitaxel, dose yeCT041 ye250 × 106masero akapihwa murwere munaGunyana 2021. Chirwere cheGrade 2 cytokine release syndrome (CRS) chakaitika, icho chakazodzorwa ne tocilizumab. Chikamu chemhinduro (PR) chakawanikwa zvichienderana ne RECIST v1.1, nekuderera kukuru kwechirwere chemapapu.
Muchiitiko chechipiri, mukadzi ane makore 75 okuberekwa akaonekwa aine kenza yepancreas yepT2N0 mushure mekunge avhiyiwa muna Chivabvu 2019. Kupararira kwemapapu kwakawanikwa mushure memwedzi mishanu panguva yekuongororwa kwakaitwa mushure mekuvhiyiwa. Kurapa kweS-1 kwakapihwa sekemotherapy yekutanga kubva muna Zvita 2019. Munguva yekuvhiyiwa kwemwaranzi yekuderedza kushushikana, kufambira mberi kwebundu kwakaonekwa mumapapu. Sezvo CLDN18.2 yakaonekwa se3+/60%, murwere akanyoreswa muongororo yekiriniki yeCT041. Mushure mekugamuchira lymphodepletion inosanganisira fludarabine, cyclophosphamide uye nab-paclitaxel, murwere akapinzwa CT041 dose ye250 × 10.6masero muna Chikunguru 2021. Murwere akawana CRS yegiredhi rechipiri, iyo yakadzorwa zvakare ne tocilizumab. PR yakawanikwa kubva pakuongororwa kwekutanga mavhiki mana mushure mekuisirwa mushonga. Maronda emapapu akapararira akazonyangarika ndokuwana mhinduro yakakwana. Bundu iri rakanga richiri pasi pekutarisirwa kusvika pakutevera kwekupedzisira muna Chikunguru 2023. Nhamba yekopi yeropa rekunze reCLDN18.2 CAR muvarwere vese yakaratidza kuwedzera nekukurumidza mushure mekuisirwa mushonga, zvichikwira mukati memavhiki maviri. Panguva imwe chete, mhedzisiro yekuronga masero yakabatidzwa ne fluorescence yakaratidza kuwedzera kwemasero eropa rekunze reCD8 T nemasero eTreg, pamwe nekuderera kwemasero eCD4 T nemasero eB. Kuchinja uku mumasero ekudzivirira muviri kwakaratidza kuramba kuripo zvakanyanya zvichienzaniswa nekuchinja kwemazinga e cytokine.
Parizvino, kune mimwe miedzo yakawanda yeCAR-T muChina, uye vari kutsvaga varwere. Kuti muwane mazano pamusoro pemishonga mitsva netekinoroji, munogona kubata Beijing South Region Oncology Hospital International Department.
Nhamba yefoni: 4008803716
Imeyili：myimmnet@163.com
Mareferensi
1. https://www.carsgen.com/en/news/carsgen-presents-updated-results-on-satri-cel-in-nature-medicine-and-at-2024-asco/
2.https://www.nature.com/articles/s41591-024-03037-z
3.https://www.carsgen.com/media/fooloi3a/ct041-cg4006-asco-2024_v3-0_20240603.pdf
4. https://jhoonline.biomedcentral.com/articles/10.1186/s13045-023-01491-9
Nguva yekutumira: Mbudzi-21-2024